

REMARKS/ARGUMENTS

Status of the Claims

Claims 5, 20, and 25 to 31 were previously pending and remain pending without further amendment.

All the claims stand rejected pursuant to 35 U.S.C. §112, first paragraph, for an alleged lack of enablement.

Response to the Enablement Rejection

The Office Action acknowledged that the specification provided sufficient guidance for the inhibition of a viral infection of a cell *in vitro*. However, the Examiner was concerned about enablement of the *in vivo* subject matter of the claims. To address this remaining concern, the Applicants provide a declaration with experimental data showing the claimed subject matter works *in vivo* in accordance with the teachings of the specification. Accordingly, the Applicants respectfully request that this grounds of rejection be reconsidered and withdrawn.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance. The issuance of a formal Notice of Allowance at an early date is respectfully requested.


Further, the Commissioner is hereby authorized to charge any additional fees or credit any overpayment in connection with this paper to Deposit Account No. 20-1430.

Appl. No. 10/512,124
Amdt. dated January 26, 2010
Reply to Office Action of March 4, 2009

PATENT

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,



Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 415-576-0300
Attachments
FJM:fjm
62419601 v1